Proglucagon-derived peptides: mechanisms of action and therapeutic potential (Q34452524)

2 August 2017

1 reference

title

Proglucagon-derived peptides: mechanisms of action and therapeutic potential (English)

1 reference

2 August 2017

2

Daniel J Drucker

1 reference

2 August 2017

Elaine M Sinclair

1

1 reference

2 August 2017

publication date

1 October 2005

1 reference

2 August 2017

1 reference

2 August 2017

volume

20

1 reference

2 August 2017

page(s)

357-365

1 reference

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Modulation of specific intestinal epithelial progenitors by enteric neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Diverse causes of hypoglycemia-associated autonomic failure in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Hypoglycemia in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Nutrient, neural and endocrine control of glucagon-like peptide secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Neural regulation of glucagon-like peptide-1 secretion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Expression cloning and signaling properties of the rat glucagon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon and regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Effect of glucagon, glicentin, glucagon-like peptide-1 and -2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Relative quantitative analysis of glucagon receptor mRNA in rat tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

The essential role of glucagon in the pathogenesis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression1This work was supported by a grant from the Crohn's and Colitis Foundation of America.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Short-term Administration of Glucagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glicentin inhibits gastric acid secretion in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

Glucagon-Like Peptide-2 Inhibits Centrally Induced Antral Motility in Pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FPHYSIOL.00030.2005

10.1152/PHYSIOL.00030.2005

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference